When diagnosed with prostate cancer a patient with his physician are faced with the decision if and how to treat it. If the physician and patient choose to treat the cancer, the risk of metastasis may be reduced, but the side effects can be rather severe. On the other hand, aggressive forms of prostate cancer require immediate and decisive attention. An assay capable of precisely assessing metastatic potential of the disease would thus be beneficial to physicians and their patients when choosing an appropriate treatment. We are collaborating with Columbia’s medical campus to develop assays, which could help determine aggressiveness of prostatic neoplasms.
